Phreesia press release ( PHR ): Q4 GAAP EPS of $0.02 misses by $0.04 . Revenue of $127.07M (+15.9% Y/Y) beats by $0.44M . More on Phreesia Seeking Alpha’s Quant Rating on Phreesia Historical earnings data for Phreesia Financial information for Phreesia

BURLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index, today announced its financial results for the fiscal first quarter 2026, which ended on February 28, 2026. Progress is the trusted provider of AI-powered digital experience and infrastructure software.

MONTRÉAL, 30 mars 2026 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE et TSX: TFII), un chef de file nord-américain du secteur du transport et de la logistique, a annoncé aujourd'hui qu'elle communiquera ses résultats financiers pour le premier trimestre clos le 31 mars 2026 par voie d’un communiqué de presse le lundi 27 avril 2026 après la fermeture des marchés. La société tiendra une webdiffusion pour la communauté des investisseurs avec Alain Bédard, président du conseil, président et chef de la direction, et David Saperstein, chef de la direction financière, le lundi 27 avril 2026 à 17h00, heure de l'Est, pour discuter des résultats.

Lexeo Earnings release

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog

MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the first quarter ended March 31, 2026 via news release on Monday, April 27, 2026 after market close. The company will host a webcast with Alain Bédard, Chairman, President and Chief Executive Officer, and David Saperstein, Chief Financial Officer, on Monday, April 27, 2026 at 5:00 PM Eastern Time, to discuss results.

Revenue growth expected to accelerate in 2026

SAN JOSE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leading provider of augmented and virtual reality (AR/VR) solutions for education, is announcing its financial results for the three and twelve months ended December 31, 2025.

RenovoCath ® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization

NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter and full year ended December 31, 2025.

APC (Nasdaq: APC) today announced financial results for the fourth quarter and the full year ended December 31, 2025

dem10/E+ via Getty Images I see a similar pattern to what happened nearly a year ago during Trump's tariff sell-off. However, I am not buying the dip yet despite the fundamentals of the high-growth pockets in the market (mainly beneficiaries from the AI data center buildout) remaining intact. Trying to time the bottom of a selloff is often a sucker's bet, but I'm more than happy to take this one. Why? So far, I am not seeing any signs of capitulation. Since the war began, the SPY hasn't seen a single 2% drop in one day. Let alone a 4% drop like in April last year. On top of that, the S&P 500 is still in a very awkward place right now from a technical perspective, with poor breadth in pretty much all sectors except energy. Guidance Terminal | Market breadth and returns across all 11 sectors | 1-month timeframe In this piece, I will focus on the most recent data that tries to put a number on the global impact of higher oil prices due to the conflicts in the Middle East. My view is that this data is overly pessimistic. The U.S. consumer is starting to sweat about higher-for-longer gas prices, although I take the survey data with skepticism. Overall, I am staying on the sidelines, as I don't think the lows are behind us. I still see the SPY at $610-$620 in the first half of the year, followed by a rally in the second half, as the oil shock fades (similarly to the tariff fears last year). This is an exogenous event, and I strongly believe it will be transitory, even though "experts" suggest otherwise. I discuss more below. OECD Cuts the Quality of Its Global Outlook The Organisation for Economic Co-operation and Development released its interim report last Thursday, showing a 1.2 percentage point increase in inflation to 4.0% for G20 countries this year. OECD The reason I'm highlighting this report is that it's the first main study since the war that tries to quantify the impact of higher for longer oil prices due to the Strait of Hormuz being blocked. Notably, this orga...

格隆汇3月31日｜当地时间3月30日，伊朗第一副总统阿雷夫警告美国总统特朗普不要派兵攻打伊朗哈尔克岛。阿雷夫表示，特朗普可以决定是否向哈尔克岛派兵，但能否从那里撤军将不由美方掌控，因为“没有人能从地狱里活着回来”。哈尔克岛位于波斯湾西北部，距离伊朗海岸大约25公里，长约6公里、宽约3公里，是伊朗最大原油出口基地，伊朗90%的原油都从这里出口。

EschCollection/DigitalVision via Getty Images Healthcare diagnostics has been one of my favorite industries to cover, but they have been dealing with macroeconomic headwinds, pricing pressures from payers, and scrutiny over reimbursement. As a result, many of my healthcare diagnostic stocks are struggling to make gains, even as these companies continue to report clinical and commercial progress. The market’s neglect has produced some intriguing opportunities to invest in companies that have significant clinical power but also offer scalable business models. Castle Biosciences, Inc. ( CSTL ) is currently showing an opportunity as a leader in precision diagnostics for a variety of cancer diagnostics, including their melanoma product, DecisionDx-Melanoma. The company is set to present updated data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, showing that their DecisionDx-Melanoma test can help stratify mortality risk within AJCC stages for patients with cutaneous melanoma (CM). Although this data presentation might not be a catalyst for the stock, I’m more interested that the company has the evidence to show that DecisionDx-Melanoma enables personalized care for patients and providers, while commercially, we could still see additional adoption, which would help revitalize the share price. As a result, I’m looking to start a pilot position in the immediate term and will look to build a position over the course of 2026 as the company invests in growth. I intend to provide a brief background on Castle Biosciences and their current performance. Then, I will discuss why I’m bullish on DecisionDx-Melanoma and why I’m looking for entry in the immediate term. I will also point out some downside risks that investors need to consider when managing their CSTL position. Finally, I take a look at CSTL’s daily chart to see if I can identify an entry point. Background on Castle Biosciences Castle Biosciences offers patient-centered genomic and molecular tests to ...

Key facts: India draft IT rules; GOOG-Starcloud pact; GOOG Maps EV TradingView

格隆汇3月31日｜衡量美元对六种主要货币的美元指数当天上涨0.36%，在汇市尾市收于100.508。截至纽约汇市尾市，1欧元兑换1.1457美元，低于前一交易日的1.1508美元；1英镑兑换1.3186美元，低于前一交易日的1.3266美元。1美元兑换159.58日元，低于前一交易日的160.38日元；1美元兑换0.8000瑞士法郎，高于前一交易日的0.7983瑞士法郎；1美元兑换1.3926加元，高于前一交易日的1.3892加元；1美元兑换9.5556瑞典克朗，高于前一交易日的9.4751瑞典克朗。

Annexon Biosciences press release ( ANNX ): Q4 GAAP EPS of -$0.28 beats by $0.04 . Cash, cash equivalents and short-term investments were $238.3 million as of December 31, 2025, including $86.3 million in gross proceeds from a November 2025 public offering. Based on focused investments in its lead late-stage programs, Annexon expects to fund operations and anticipated milestones into the second half of 2027. More on Annexon Biosciences Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials - Slideshow Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials Transcript Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences

格隆汇3月31日｜截至当天收盘，纽约商品交易所5月交货的轻质原油期货价格上涨3.24美元，收于每桶102.88美元，涨幅为3.25%；5月交货的伦敦布伦特原油期货价格上涨21美分，收于每桶112.78美元，涨幅为0.19%。

Douglas Rissing "The current stance of monetary policy is well positioned to balance the risks to our maximum employment and price stability goals," said John Williams, a permanent member of the Federal Open Market Committee. The president of the Federal Reserve Bank of New York participated in a conversation at an event organized by the Staten Island Economic Development Corporation. "Despite heightened uncertainty around the impact of trade and other policies, the economy has been resilient, with growth remaining solid through last year and into the beginning of this year," said Williams. "Consumer spending has been resilient, and business investment has been strong. And the unemployment rate has stabilized over recent months. Inflation remains somewhat elevated due to the effects of tariffs, but those effects should begin to dissipate later this year," he added. Williams said it's an unusual time for the economy, with substantial risks and high uncertainty - particularly around the economic effects of the Middle East conflict. "In assessing the future path of monetary policy, my views, as always, will be based on the evolution of the totality of the data, the economic outlook, and the balance of risks to the achievement of our maximum employment and price stability goals," he said. Turning to one side of the Fed's dual mandate - maximum employment - "We are getting mixed signals, with some key indicators showing signs of steadying while others are suggesting a weakening labor market." The FOMC voting member mentioned a low-hire, low-fire environment in existence currently, and said, "The low hiring rate, along with an increase in long-term unemployment, may be contributing to a somewhat more pessimistic perception among households than other indicators of the labor market might suggest." For the other side of the Fed's mandate - price stability - "Inflation is experiencing its own unusual crosscurrents due to the effects of tariffs and developments in the Middle ...

格隆汇3月31日｜美股周一收盘，道指初步收涨0.1%，标普500指数跌0.39%，纳指跌0.73%。英伟达(NVDA.O)跌1%，闪迪(SNDK.O)跌7%，美光科技(MU.O)跌9.8%，英特尔(INTC.O)跌超4%。纳斯达克中国金龙指数收跌0.35%，蔚来汽车(NIO.N)涨3.8%，爱奇艺(IQ.O)涨5.8%。

格隆汇3月31日｜美联储威廉姆斯：预计今年通胀率将收于2.75%，2027年回落至2%。

Shareholders that lost money on Oracle Corporation(ORCL) Urged to Join Class Action – Contact ... Bluefield Daily Telegraph

美股三大指数收盘涨跌不一，标普500指数跌0.4%，道指涨0.11%，纳指跌0.74%。大型科技股方面，Meta涨2.03%，英伟达跌1.40%，特斯拉跌1.81%，超威半导体跌2.95%，阿斯麦跌3.72%，英特尔跌4.50%，美光科技跌9.88%。中概股方面，蔚来涨3.86%，携程涨1.40%，小鹏汽车跌1.21%，拼多多跌1.39%，哔哩哔哩跌2.87%。

格隆汇3月31日｜美联储威廉姆斯：低就业增速可能加剧经济悲观情绪。

格隆汇3月31日｜WTI原油日内大涨3.00%，现报104.56美元/桶。

格隆汇3月31日｜美联储威廉姆斯：通胀预期与2%通胀目标一致。

格隆汇3月31日｜美联储威廉姆斯：预计今明两年失业率将小幅下降。

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-2519 1 . AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis’ proprietary platform. The Company’s lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis’ miniprotein radioconjugates are designed to selectively deliver actinium-225 ( 225 Ac), a highly potent alpha-emitting radioisotope, to target-expressing tumors. The Company also provided business updates and reported financial results for the year ended December 31, 2025.

Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results